These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 14633703

  • 1. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
    Cancer Res; 2003 Nov 15; 63(22):7777-84. PubMed ID: 14633703
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N.
    Cancer Res; 2003 May 01; 63(9):2139-44. PubMed ID: 12727831
    [Abstract] [Full Text] [Related]

  • 3. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.
    Cancer Res; 2001 Sep 01; 61(17):6583-91. PubMed ID: 11522658
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG, Matts RL.
    Exp Cell Res; 2005 Jul 01; 307(1):212-23. PubMed ID: 15922741
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M, Liu F, Tavorath R, Rosen N.
    Cancer Res; 2000 Jul 15; 60(14):3940-6. PubMed ID: 10919672
    [Abstract] [Full Text] [Related]

  • 6. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T, Lowell AM, Engelman JA, Shapiro GI.
    Cancer Res; 2005 Jul 15; 65(14):6401-8. PubMed ID: 16024644
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 15; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 14. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
    Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D.
    Cancer Res; 2005 Mar 01; 65(5):1858-67. PubMed ID: 15753384
    [Abstract] [Full Text] [Related]

  • 15. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 01; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
    Moasser MM, Basso A, Averbuch SD, Rosen N.
    Cancer Res; 2001 Oct 01; 61(19):7184-8. PubMed ID: 11585753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.